Top 10 Global Pharma Companies by 2023 Revenue All Active in Cell and Gene Therapy – IPO Filing Submitted

According to the revenue of major pharmaceutical companies in 2023, an industry media recently released the ranking of the top 10 global pharmaceutical companies. In this list, Johnson & Johnson, Roche, and Merck & Co., Inc. ranked in the top three.

The world's top 10 pharmaceutical companies mentioned above have all laid out plans in cell and gene therapy (CGT).，Cell therapy refers to a treatment method that uses the patient's own (or allogeneic) adult cells (or stem cells) to repair tissues and organs, including immune cell therapy, stem cell therapy, and other cell therapies.In a broad sense, gene therapy drugs include DNA drugs based on DNA modification (such as in vivo gene therapy drugs based on viral vectors, ex vivo gene therapy drugs, naked plasmid drugs, etc.) and RNA drugs (such as antisense oligonucleotide drugs, siRNA drugs, and mRNA gene therapy, etc.); In a narrow sense, gene therapy drugs mainly include plasmid DNA drugs, gene therapy drugs based on viral vectors, gene therapy drugs based on bacterial vectors, gene editing systems, and cell therapy drugs with ex vivo gene modifications, etc.

Classification of Gene Therapy (Source: BioEpoch)

Johnson & Johnson

Revenue in 2023:$85.2 billion

Headquarters:New Brunswick, New Jersey

Recommended reading article link:

1）Johnson & Johnson's AAV Gene Therapy for Ophthalmology Approved for Clinical Trials in China

2) Johnson & Johnson's Ophthalmic Gene Therapy AAV5-hRKp.RPGR Proposed for Inclusion in Breakthrough Therapy

3) Ophthalmology Gene Therapy! Johnson & Johnson's AAV-RPGR for Treating X-linked Retinitis Pigmentosa (XLRP): Significant Vision Improvement!

4) Johnson & Johnson Returns NASH RNAi Drug Rights

Roche

Revenue in 2023:$65.627 billion

Headquarters:Basel, Switzerland

Recommended reading article link:

Over $6 Billion! Roche Enters the Universal CAR-T Therapy Field

Over $1 Billion! Roche Collaborates with Avista to Develop Next-Generation AAV Gene Therapy Vectors for Ocular Diseases

3) The world's first DMD gene therapy is nearing market release as the FDA accepts Roche and Sarepta's BLA application for DMD gene therapy.

MSD

Revenue in 2023:$60.115 billion

Headquarters:Kenilworth, New Jersey

Recommended reading article link:

1) Milestone: Merck/Moderna Tumor Neoantigen mRNA Vaccine Initiates Phase III Clinical Trial

2) MSD Acquires Viralytics for $396 Million, Expanding Oncolytic Virus Product Line

3) MSD Invests Over $3.5 Billion in Circular RNA

Pfizer

Revenue in 2023:$58.496 billion

Headquarters:New York City

Recommended Reading Article Link:

1) Pfizer's Hemophilia B AAV Gene Therapy Approved for Marketing

$1 Billion! AstraZeneca Acquires Pfizer Gene Therapy Product

3) $300 Million! Pfizer Acquires a Novel AAV Capsid Targeting the Nervous System, Licensor’s Stock Price Surges 17%

4) New Pioneer Develops Macrophage Therapy, Secures $70 Million Investment from Pfizer

5) Pfizer's DMD Gene Therapy Phase 3 Clinical Trial Resumes, Solid Bio Updates DMD Gene Therapy Clinical Research Plan

6) Over $600 Million Boosts Development of Novel AAV Gene Therapy, Pfizer Reaches Collaboration

AbbVie

Revenue in 2023:$543.18 billion

Headquarters:North Chicago, Illinois

Recommended reading article link:

1）Producing CAR-T Inside the Body! AbbVie Strikes Over $1.4 Billion Collaboration

2) Gene Therapy for Alzheimer's Disease: AbbVie Collaborates with Voyager Therapeutics on Research and Development

3Over $660 Million! AbbVie and Capsida Collaborate on Gene Therapy for Eye Diseases

Bayer

Revenue in 2023:USD 51.662 billion

Headquarters:Leverkusen, Germany

Recommended reading article link:

1) Bayer Co.Lab Collaborative Platform Lands in China for the First Time, Promoting Cutting-edge Innovations in Cell and Gene Therapy Fields

2) Bayer Invests $250 Million in New Cell Therapy Plant

3) Metagenomi, a gene-editing technology company, secures nearly $300 million in Series B funding from Moderna, Bayer, and others to accelerate the development of gene-editing products.

4) A subsidiary of Bayer has been approved to conduct clinical trials for Huntington's gene therapy

5) Bayer Advances Two First-in-Class Cell and Gene Therapies for Parkinson's Disease

Sanofi (Sanofi)

Revenue in 2023:$46.709 billion

Headquarters:Paris, France

Recommended reading article link:

1) €1.375 Billion! Sanofi Boosts Investment in NK Cell Therapy Field

$400 Million! Sanofi Collaborates with RNA Therapy Start-Up to Develop Antibody-RNA Conjugate Drugs

3) $1 Billion: Sanofi Collaborates with Scribe to Develop CAR-NK Therapy Using Gene Editing Technology

4) $3.2 Billion! Sanofi Acquires mRNA Company Translate Bio

AstraZeneca

Revenue in 2023:$45.811 billion

Headquarters:Cambridge, UK

Recommended reading article link:

1) Gracell Biotechnologies Announces Official Merger into AstraZeneca Group

2) AstraZeneca Invests $300 Million to Build Cell Therapy Factory

3) AstraZeneca Acquires Icosavax and Its Virus-Like Particle Platform Technology for $1.1 Billion

4) AstraZeneca Establishes R&D Center in Hong Kong to Advance Medical Research Related to Drug Development in Key Therapeutic Areas, Including Cell Therapy and Gene Therapy

5) AstraZeneca's $320 Million Acquisition of Neogene: A Bet on T-Cell Therapy

6) Soaring 638%! AstraZeneca Acquires Gene Therapy Company LogicBio

7) AstraZeneca Acquires Novel T-Cell Immunotherapy for Over $1.2 Billion

Novartis

Revenue in 2023:$45.44 billion

Headquarters:Basel, Switzerland

Recommended Reading Article Link:

1) $1.2 Billion! Novartis Doubles Down on Novel Gene Therapy Drugs

2) $1.1 Billion! Legend Biotech's DLL3-Targeted CAR-T Therapy Licensed to Novartis

Over 600 Million Yuan! Novartis Acquires a Gene Therapy Project

4) Novartis Releases New Data: AAV Gene Therapy Zolgensma Shows Effectiveness for Up to 7.5 Years

5) Novartis announces new development strategy, prioritizing cell and gene therapies, radioligand therapy, and xRNA in biologics and technology platforms.

6) Novartis Completes $1.5 Billion Acquisition of Ophthalmology Gene Therapy Company Gyroscope Therapeutics

7) Novartis Acquires Another Gene Therapy Startup, Arctos Medical, Showing Confidence in Optogenetics Technology

Bristol-Myers Squibb

Revenue in 2023:$45.06 billion

Headquarters:New York City

Recommended reading article link:

1) Gilead, AstraZeneca, and Bristol-Myers Squibb Explore New Directions in Cell Therapy

$4 Billion | Evotec and BMS Deepen iPSC Collaboration to Advance in Neurodegenerative Diseases

3) BMS's CD19 CAR-T Approved for Marketing in the EU

GSK

Revenue in 2023:$37.722 billion

Headquarters:Cambridge, UK

Recommended Reading Article Link:

1) GSK and Novartis Obtain Bluebird Lentivirus Patent for Development of Gene Therapy and CAR-T Cell Therapy

2) Why is GSK giving up at a critical moment?

Eli Lilly

Revenue in 2023:$34.124 billion

Headquarters:Indianapolis, Indiana

Recommended Reading Article Link:

1) $740 Million: Eli Lilly and Capsida Forge Strategic Collaboration on AAV Gene Therapy Project

2) $610 Million! Eli Lilly Acquires Gene Therapy Company Akouos

3) On the basis of a $1 billion acquisition of gene therapy company Prevail Therapeutics, Eli Lilly and Company will invest $700 million to establish the Boston Gene Therapy Research Center.

Novo Nordisk

Revenue in 2023:USD 33.771 billion

Headquarters:Bagsvaerd, Denmark

Recommended reading article link:

1) Novo Nordisk's RNAi Therapy Receives FDA Approval for Market Launch

2) Advancing into Cell Therapy! Novo Nordisk's Cell Treatment Drug HS-001 Administered to First Patient

3) Gene therapy company Freeline completes $120 million financing, Novo Nordisk Ventures joins

Recommended articles from previous issues:

CAR-T Therapy from Carsgen Therapeutics Launches at 1.15 Million Yuan, Expected Peak Annual Sales to Exceed 1 Billion Yuan

"Innovative Drugs" First Appeared in Government Work Report｜Accelerate the Development of Innovative Drugs and Other Industries, Actively Create New Growth Engines such as Biomanufacturing

Illustrated Guide to NK Cell Therapy

Two National Scientific Research Platforms Approved and Established by Subsidiaries of China National Pharmaceutical Group's China Biologic Products Have Officially Launched

FDA Lifts Clinical Hold on Iovance's TIL Cell Therapy

Differences Among CXO, CRO, CMO, CDMO, and CSO

"Biden Bill" Wind Change, CXO Soars

Huace Biomann's First TIL Cell Therapy HS-IT101 Completes First Dosing in Phase I Clinical Trial

TIL Cell Therapy Priced at 3.7 Million Shows Promising Market Potential, with First-Quarter Sales Expected to Exceed 30 Million

Synthetic Biology Ranks First!

Fosun Pharma Subsidiary’s NK Cell Therapy GCK-01 Approved for Clinical Trials

First in China: Yaotang Biotech's In Vivo Gene Editing Drug YOLT-201 Approved for Clinical Trials

Miaoshun Biotech R&D Center Officially Launched!

Guangdong Province Releases New Policy! Focuses on Five Major Projects: Gene Technology, Cell Therapy, AI + Biomedicine, and Synthetic Biology

Six Companies in China Complete New Round of Financing, Focusing on Cell and Gene Therapy Fields

Covering an area of approximately 13,000 square meters, the industrialization base project for cell therapy drugs by Senbo Biologics has been launched.

Another Global Strategic Center of a Pharmaceutical Giant Settles in Shanghai, Which Will Become an Important R&D Base in the Field of Cell Therapy

First AAV Gene Therapy for Hemophilia A Falls Far Short of Sales Expectations Last Year

Xiong'an Officially Issues! Support for the Development of Modern Life Sciences and Biotechnology Industries such as Cell Therapy, Genetic Engineering, and Tissue Engineering

Government Invests 6 Billion Yuan to Fund the Establishment of a Life Health Research Institute, Focusing on Cutting-edge Topics such as Cell and Gene Therapy

NVIDIA CEO Jensen Huang: The Era of Having to Learn Computer Science and Programming is Over, the Next Golden Track is Life Sciences and Engineering

First in China: Universal CAR-NK for Treating Systemic Lupus Erythematosus Approved for Clinical Trials

Beijing to Focus on Cell Gene Therapy, Synthetic Biological Manufacturing, and Other Cutting-Edge Emerging Fields as Key Tasks for 2024

FDA Releases Guidelines for the Development of Gene-Editing Therapies and CAR-T Therapies (Full Text of Guidelines Attached)

CDE Releases "Technical Guiding Principles for Non-Clinical Research of Human Stem Cell Products"

CRISPR/Cas9 Gene Editing Therapy Receives FDA Approval for Treating β-Thalassemia